BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Frequently asked questions
What sector does BioInvent International AB (BINV) operate in?
BioInvent International AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BioInvent International AB (BINV) current stock price?
As of the latest data, BioInvent International AB stock price is SEK 25.10, with a previous close of SEK 23.80. BioInvent International AB gained SEK 1.30 in the last trading session, representing a 5.46% increase.
What is BioInvent International AB (BINV) current market capitalization?
BioInvent International AB market cap is approximately 1.65 billion.
What is BioInvent International AB (BINV) Earnings Per Share (EPS)?
The trailing EPS is -SEK 5.10, and the forward EPS is -SEK 5.61.
What is BioInvent International AB (BINV) EBITDA?
BioInvent International AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -116.89 million.
Does BioInvent International AB (BINV) pay dividends?
No. BioInvent International AB does not pay a dividend.
How did BioInvent International AB (BINV) perform in its most recent earnings report?
In the last report (March 31, 2026), BioInvent International AB posted an EPS surprise of 4.74% and a revenue surprise of -9.78%.
When is BioInvent International AB (BINV) next earnings report?
BioInvent International AB is expected to release its next earnings report on June 30, 2026.
What is BioInvent International AB (BINV) beta (volatility) score?
BioInvent International AB has a beta of 0.018, indicating lower volatility than the overall market.
